Author:
Schinner Lena,Nagels Klaus,Scherf Julia,Schmaderer Christoph,Heemann Uwe,Küchle Claudius,Hannemann Liya
Abstract
Abstract
Background
Sarcopenia is highly prevalent in haemodialysis (HD) patients and linked to a poor prognosis regarding comorbidities and premature mortality. Previous studies assessed the effects of neuromuscular electrical stimulation in haemodialysis patients. This study adds to the relevance of neuromuscular electrical stimulation (NMES) applications combined with a virtual reality (VR) distraction to increase intensity, dosage, and efficiency of NMES and slow sarcopenia progression in HD patients.
Methods
We conducted a 12-week multicenter prospective randomised controlled trial. The patients were randomly assigned to one of the three groups: neuromuscular electrical stimulation with or without combined virtual reality distraction or control group.
Results
The final analysis included 32 haemodialysis patients (mean age of 68 ± 10 years, 26 men). Interaction effects between groups and time (12 weeks) were significant regarding serum albumin levels (p = 0.008) and left quadriceps femoris muscle (QFM) force (p = 0.026). Both endpoints were increased in the NMES compared to the CO group at the end of the intervention. The NMES group increased serum albumin levels significantly after 12 weeks. The main effect of time was an increase in mean right QFM force between beginning and end of the intervention (p = 0.021). Functional capacity improved after 12 weeks in the NMES and NMES + VR but not in the control group, with a significant difference between the three groups (p = 0.022). Weight and body mass index increased in the NMES and NMES + VR groups, albeit not significantly. The effects of VR distraction on NMES efficiency were inconclusive.
Conclusion
Intradialytic NMES increases serum albumin level, functional capacity, muscle strength in lower limb and in tendency weight and body mass index of HD patients. Effects on VR distraction are inconclusive. Large-scaled follow-up studies on integrated sports programs with NMES and active training in combination with VR as distraction and motivation accelerator are needed.
Trial registration
German Clinical Trial Register: DRKS00029276 (Retrospectively registered: 30/06/2022).
Funder
Technische Universität München
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–50. https://doi.org/10.1016/j.kint.2019.07.012.
2. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82. https://doi.org/10.1016/S0140-6736(14)61601-9.
3. Hämodialyse BJ. In: Kuhlmann U, Böhler J, Luft FC, Kunzendorf U, Alscher MD, editors. Nephrologie: Pathophysiologie, Klinik, Nierenersatzverfahren. Stuttgart, New York: Georg Thieme Verlag; 2015. p. 671–711.
4. Ferrari U, Drey M. Die aktuelle Sarkopenie-Definition. DMW (1946). 2020;145:1315–9. https://doi.org/10.1055/a-0986-2818.
5. Mori K, Nishide K, Okuno S, Shoji T. Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. BMC Nephrol. 2019;20:105.